INTRODUCTION
According to our current understanding, pathological changes in the microtubule-associated protein tau in Alzheimer's disease (AD) may be elicited by soluble oligomeric forms of amyloid-b (Ab) (1-4), which in turn leads to the dysfunction and degeneration of the elements subserving cognition, including neuronal cells and their synapses in the brain (5) . In the past decade, several groups have documented the effects of various putative endogenous soluble forms of Ab oligomers, most notably dimers, trimers, and Ab*56, on memory (6-8) and on its presumed physiological substrate long-term potentiation (9) (10) (11) .
The Ab assembly, called Ab*56, was originally identified in brain tissue of young amnestic Tg2576 mice overexpressing a mutant form of the human amyloid precursor protein (APP) used as a model of AD (8) . Similar observations from several independent groups validated the existence of this Ab species in other cognitively impaired APP transgenic mouse models (12) (13) (14) (15) . In addition, brain infusion of Ab*56 purified from APP mouse brain tissue caused transient memory deficits in young healthy rodents, demonstrating the memory impairing capability of this Ab oligomer (8) . Recent studies further confirmed the presence of Ab*56 in postmortem human brain tissue and cerebrospinal fluid (16) . In these cross-sectional studies, an abnormal increase in abundance of this Ab oligomer in the brain was seen in samples from subjects in their fifth decade of life, preceding increases in Ab dimers and trimers by two decades and coinciding with the age at which subtle cognitive deficits first appear (17) . Notably, this increase in brain Ab*56 was associated with aberrantly increased phosphorylation and missorting of tau typically seen in the early stages of the symptomatic phase of AD (16) . Overall, these findings indicate that the Ab oligomer Ab*56 might alter memory and neuronal function during the presymptomatic phase of AD despite recent independent reports of a potential link between a putative Ab dodecamer and AD vulnerability in the temporal cortex (18) . To further understand the role of Ab*56 in AD and to develop potential strategies aiming at countering its deleterious effects on cognition, we sought to identify the molecular mechanism by which Ab*56 disrupts tau biology and neuronal physiology.
RESULTS

Ab*56 interacts with N-methyl-D-aspartate receptors in an age-dependent manner
We previously reported that Ab*56 can be detected in brain lysates (enriched in extracellular proteins) from Tg2576 mice starting at 6 months of age (8) . This oligomeric Ab assembly can also be found in membraneassociated lysates containing postsynaptic density (PSD) proteins, including PSD-95 (2, 13, 19) . The presence of Ab*56 in this compartment implies a possible binding of this Ab molecule to a putative receptor, thereby transducing a deleterious intracellular biological signal. Because Ab*56 causes memory impairment, we sought to determine whether Ab*56 could interact with glutamatergic receptors, because they are critically involved in the molecular substrate of memory at a cellular level. We therefore performed coimmunoprecipitation experiments on membrane extracts using various antibodies against receptors previously described as interacting with synthetic Ab oligomers as well as distinct subunits of the glutamatergic receptors. These included the following: N-methyl-D-aspartate receptor (NMDAR) subunits GluN1, GluN2A, and GluN2B; a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) subunits GluA1 and GluA2; a7-acetylcholine receptor subunit (a7); metabotropic glutamate receptor 5 (mGluR5); the receptor tyrosine kinase Ephrin B2; cellular prion protein (PrP C ); and the receptor for advanced glycation end-products (RAGE) (Fig. 1A) . We observed that only antibodies against GluN1, GluN2A, and GluN2B pulled down a 6E10-immunoreactive species consistent with Ab*56 (Fig. 1A) . The relative amount of Ab*56 detected varied across immunoprecipitations with different GluN antibodies and appeared to reflect the abundance of the respective receptor subunits. In addition, no other Ab species were immunoprecipitated as detected by 6E10. Notably, under our experimental conditions, antibodies targeting other glutamatergic receptors were unable to capture soluble Ab species (Fig. 1A) . By contrast, dimeric Ab was pulled down using PrP C antibodies, as previously reported by our group (2), whereas monomeric Ab coimmunoprecipitated with RAGE. Using either membrane-associated or extracellular-enriched protein fractions known to contain Ab*56 but different amounts of the NMDAR subunit GluN1, we confirmed that Ab*56 coimmunoprecipitated with GluN1 in membrane-associated extracts of 15-month-old Tg2576 mice ( fig.   S1A ). Reverse coimmunoprecipitations with two Ab antibodies, 6E10 or 4G8, further supported our initial results ( fig. S1 , B and C). Similar findings were observed using the A11 antibody raised against nonfibrillar amyloid oligomers (Fig. 1B) , confirming the oligomeric nature of the Ab assembly pulled down by GluN1. In addition, the relative abundance of putative Ab*56-GluN1 complexes in membrane-associated lysates of Tg2576 forebrain tissue increased with aging, comparing transgenic mice from 2 to 24 months of age ( Fig. 1C and fig. S1D ). To demonstrate that these observations are not restricted to the Tg2576 line, we performed immunoprecipitations of GluN1 complexes in a different APP transgenic mouse line with lower APP expression [J20 line; (20) ]. We selected animals at 3 and 6 months of age because they were previously described to display cognitive deficits and to express Ab*56 in their brain tissue (13, 21) . As predicted, we detected Ab*56-GluN1 complexes in membraneassociated lysates from young J20 animals ( fig. S1E ). To validate these observations and assess their specificity, we measured the relative abundance of APP and/or Ab, A11-positive type I Ab oligomers, and OC (amyloid fibril antibody)-positive type II oligomers in membrane-associated lysates by nondenaturing dot blotting (22) . We found that A11-immunoreactive species rose with age starting at 7 months. This profile contrasted with that observed for both APP/Ab and type II oligomers ( fig. S2 ). Together, these biochemical analyses of Tg2576 and J20 mice suggested the existence of an Ab*56-NMDAR complex.
To demonstrate that Ab*56 might directly interact with NMDAR subunits, we first isolated NMDARs from brain tissue of middle-aged 15-month-old Tg2576 mice by immunoaffinity capture and segregated putative NMDAR complexes by size exclusion chromatography (SEC; fig. S1, F to H). We observed that Ab*56 coeluted with GluN1 in SEC fractions at molecular weights consistent with those of heteromeric NMDARs. Furthermore, nondenaturing dot blot analysis showed reactivity for A11 and GluN1 in the same fraction, proving the interaction between a type I Ab oligomer (22) and NMDAR. Next, we applied Ab*56 purified from APP transgenic mouse brains onto primary cortical neurons and human embryonic kidney (HEK) 293 cells transfected with GluN1 and/or GluN2B. Vehicle Ab and monomeric Ab were used as negative controls. Preparations of isolated Ab species including monomers and Ab*56 derived from APP transgenic animals were obtained using a modified protocol previously described for purifying endogenous Ab oligomers from human brain tissue ( fig. S3) (2) . Purified Ab*56 was applied to cells for 60 min, as previously reported (2) . Quantitative reverse transcription polymerase chain reaction (RT-PCR) analysis of GluN mRNAs and dendritic spine imaging using Coimmunoprecipitation of Ab*56 with NMDAR subunits (GluN1, GluN2A, and GluN2B), AMPAR subunits (GluA1 and GluA2), a7-nicotinic acetylcholine receptor subunit (a7), mGluR5 (R5), or Ephrin B2 (B2) in membrane extracts from the forebrain of Tg2576 mice. Ab was detected with 6E10. Blot is representative of three experiments (n = 6 mice per group). IP, immunoprecipitation; WB, Western blot; IgG, immunoglobulin G. (B and C) Western blots (B) and quantitation (C) of coimmunoprecipitation of Ab*56 with GluN1 in membrane extracts from Tg2576 mice and a wild-type (WT) control. Antibody A11 was used to detect oligomeric Ab. Data are means ± SD from n = 5 mice per group. ) primary cortical neurons. Neurons were also labeled for the dendritic neuronal marker microtubuleassociated protein 2 (MAP2) (blue). n = 6 dishes per group. Veh., vehicle. (E) Software-assisted colocalization analysis of Ab*56 and GluN1 on WT and Prnp-null neurons [six regions of interest (ROIs) per dish; n = 6 dishes per group]. (F) Western blots comparing GluN1 protein amounts in primary neurons and in HEK293 cells expressing GluN1. (G) Representative confocal images of Ab*56 (A11; magenta) binding to HEK293 cells transfected with GluN1 (red) and/or GluN2B-enhanced green fluorescent protein (green). Arrowheads indicate colocalization between Ab*56 and GluN1. n = 6 to 8 dishes per condition. Scale bars, 15 mm.
various fluorescent reporters validated the maturity of cultured cortical neurons ( fig. S4 ), consistent with earlier reports (23) (24) (25) (26) . We observed that Ab*56 readily colocalized with GluN1 on the surface of primary cortical neurons (Fig. 1D) . Because some Ab species bind to PrP C (2, 27-29), we also analyzed Ab*56 binding to GluN1 in Prnp-null neurons and found that binding occurs in a PrP C -independent manner (Fig. 1, D and E) . Finally, we found that Ab*56 bound to HEK293 cells transfected with GluN subunits, in which GluN expression was comparable to that detected in primary neurons (Fig. 1F) . To assess which subunit might be responsible for the interaction, we subsequently transfected cells with individual GluN subunits. After the application of Ab, Ab*56 readily colocalized with GluN1 but not with GluN2B, indicating that Ab*56 is binding to the NMDAR through a direct interaction with GluN1 (Fig. 1G) . These results suggest that GluN1 and Ab*56 might interact directly in brain tissue.
Ab*56 enhances synaptic NMDAR-dependent calcium influx Next, we sought to examine the effect of Ab*56 on synaptic NMDARdependent calcium influx. Calcium transients were visualized in mouse cortical neurons transfected with the genetically engineered calcium sensor GCaMP6f (30) , and bicuculline/4-aminopyridine (Bic4AP) was applied onto cells for 15 s to stimulate the NMDAR, because this paradigm was previously shown to selectively activate synaptic NMDARs in primary cultured neurons (26, 31) . In the absence of Ab*56, the Bic4AP pulse induced a lasting elevation of GCaMP6f fluorescence (Fig. 2, A and  B ). In the presence of 2.5 pM Ab*56 (a 30-min pretreatment followed by a 5-min recording period), application of Bic4AP resulted in an enhanced and sustained influx of calcium mediated by synaptic NMDARs (Fig. 2, A and B). Upon calculating the peak amplitude and the global magnitude of the recorded responses (Fig. 2, C and D) , Ab*56 was found to potentiate synaptic NMDAR-induced Ca 2+ influx by~4.5-fold compared to cells exposed only to vehicle (a respective 4.99 ± 0.16-and 3.94 ± 0.16-fold increase compared to control cells).
To demonstrate that Ab*56 specifically enhances Ca 2+ currents mediated by NMDARs, we exposed the cells to a series of sequential bath stimulations with Bic4AP before or after a 15-min exposure to 2.5 pM Ab*56; then, we subjected the cells to Bic4AP/MK801 stimulations to block opened synaptic NMDARs. Finally, the same cells were exposed to another Bic4AP bath stimulation to ensure that synaptic NMDARs were blocked (Fig. 2E) . Adding the NMDAR antagonist MK801 led to an 82% reduction in NMDAR-mediated Ca 2+ influx in cells exposed to Ab*56 (Fig. 2, E and F) . The lack of potentiated Ca 2+ influx triggered by the subsequent Bic4AP stimulation indicated that extrasynaptic NMDARs were unlikely to be involved in the potentiation induced by Ab*56 (Fig. 2, E and F) . Counterintuitively, these findings are consistent with a selective activation of synaptic NMDARs by Ab*56.
Ab*56-NMDAR complexes selectively activate Ca 2+ -dependent calmodulin kinase IIa NMDAR-mediated neuronal responses depend on the composition and subcellular localization of the receptors at the plasma membrane (synaptic or extrasynaptic) and involve distinct, opposing, or overlapping signaling pathways (32) . Briefly, the activation of extracellular signalregulated kinases (ERKs), adenosine 3′,5′-monophosphate (cAMP) response element-binding protein (CREB), and Ca
2+
-dependent calmodulin kinases (CaMKs) has been traditionally linked to mediating the effect of synaptic NMDARs. By contrast, activation of p38 kinase and Forkhead box protein O (FOXO) as well as inhibition of ERK and CREB are believed to be the downstream effectors of extrasynaptic NMDAR (32) . In addition, we included analyses of the Src kinase Fyn, considering its proposed involvement in mediating Ab-induced toxicity (2, 27, 28, (33) (34) (35) (36) . We therefore assessed key components of these major pathways in Tg2576 mice at an age when Ab*56 is present (7 months) or absent (4 months fig. S5 ). Because gene expression activity of the FOXO member FOXO-1 relies on nuclear translocation, we examined its relative abundance in extracts enriched in intracellular proteins and in those containing nuclear and membrane-bound proteins (8, 19) . Similar to other intracellular messengers, we did not observe any overt changes in the biochemical segregation of FOXO-1 across ages and genotypes ( fig. S5E) .
One of the major consequences of the activation of NMDARs is the influx of extracellular calcium ions (Ca 2+ ), thereby triggering Ca 2+ -dependent signaling molecules, including the calmodulinCaMK axis (32) . The finding that the CaMKIIa isoform has previously been linked to neuronal toxicity in neurodegenerative disorders (37, 38) , together with our results showing no changes in CREB phosphorylation mediated by CaMKIV in 7-month-old Tg2576 mice, led us to assess CaMKIIa activity by measuring its activating phosphorylation state at Thr
286
. This phosphorylation (hereafter denoted as pCaMKIIa) increased~2.5-fold in intracellular-enriched lysates of 7-month-old Tg2576 mice compared to younger 4-month-old Tg2576 mice or agematched wild-type controls (Fig. 3, A and B) . Because Tg5469 animals overexpress human wild-type APP to an extent similar to that of mutant APP in Tg2576 mice (39), we also included Tg5469 mice to our comparative analyses to evaluate potential effects of transgene-derived APP on CaMKIIa. Contrary to that in Tg2576 animals, the relative phosphorylation of CaMKIIa at Thr 286 in Tg5469 mice was indistinguishable from that of nontransgenic mice, indicating that overexpression of soluble APP-a was not responsible for increasing the observed pCaMKIIa abundance (Fig. 3, A and B) . Ab*56 abundance correlated with that of pCaMKIIa in 6-to 9-month-old transgenic animals, with no changes observed for total CaMKIIa abundance ( fig. S6 ). Using confocal imaging, pCaMKIIa immunoreactivity was markedly enhanced in the synaptic fields of Tg2576 prefrontal cortex and CA1 pyramidal neurons at 7 months of age (Fig. 3C ). In both brain regions, the observed subcellular distribution of pCaMKIIa was consistent with the translocation of CaMKII from the soma to the synapse once phosphorylated (40) . On the basis of this observation, we biochemically assessed whether pCaMKIIa was accumulating in PSD-containing lysates (membrane-associated fraction) of Tg2576 mice over time. We found that pCaMKIIa accumulated in an age-dependent manner in this fraction ( To demonstrate that Ab*56 directly caused a selective exacerbation of CaMKIIa activity, we applied soluble Ab oligomers purified from APP transgenic mouse brains at pathophysiologically relevant concentrations (picomolar to nanomolar range) to primary cultured cortical neurons. Preparations of apparent Ab monomers, dimers, trimers, and Ab*56 derived from transgenic animals were obtained using a protocol previously described for purifying endogenous Ab oligomers from human brain tissue (fig .  S3 ) (2) . Because of the low abundance of Ab*56 in brain tissue (8, 22) , Ab*56 was applied to cells in a dose-dependent manner, ranging from 1 to 25 pM. By contrast, lowmolecular weight soluble Ab species were applied at concentrations of 1 to 5 nM, previously found to be biologically active in our in vitro system (2) . To attempt inducing a sustained effect on CaMKIIa that might recapitulate the exposure of neurons to Ab*56 in vivo, primary cortical neurons were exposed to each purified Ab preparation for 60 min, as previously described ( Fig. 3F and fig. S7 ) (2) . Whereas baseline levels of pCaMKIIa were readily detected in vehicletreated neurons, application of increasing concentrations of Ab*56 induced a 
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dose-dependent potentiation of CaMKIIa phosphorylation, which plateaued at 5 pM to an average of 2.89-fold of the baseline (Fig. 3 , F and G). On the basis of these data, we chose to use Ab*56 at a concentration of 2.5 pM for all subsequent experiments. Time course experiments using 2.5 pM Ab*56 indicated that CaMKIIa activity peaked after 1 hour of treatment and declined to baseline within 8 hours (Fig. 3 , H and I). Consistent with the increase in CaMKIIa phosphorylation observed by Western blotting, confocal immunofluorescence analyses revealed both an increase in pCaMKIIa immunoreactivity ( fig. S8A ) and a translocation of pCaMKIIa to PSDs in neurons treated with Ab*56 for 60 min ( fig. S8 , A to C). Z-stack reconstruction analyses confirmed a 2.53-fold increase in pCaMKIIa colocalization with PSD-95 in neurons exposed to Ab*56 (Fig. 3, J and K) . Furthermore, assessment of neuronal cell death using lactate dehydrogenase (LDH) assays indicated that Ab*56 was not cytotoxic at the concentrations used in our experimental conditions ( fig. S9, , the phosphorylation of which is increased in AD brain tissue (41, 42) . Of particular interest, phosphorylation at Ser 416 has been proposed to induce a conformational change in the tau protein (41) . We therefore examined Tg2576 mice for CaMKII-related changes in tau along with other changes commonly associated with AD ( Fig. 4A ; n = 6 to 9 animals per age per genotype). Across transgene and age groups, no obvious changes in phosphorylation were detected at Tyr (Fig. 4,  A and B) . However, we detected a~2.7-fold increase in phosphorylation at Ser 202 and Ser 416 in 7-month-old Tg2576 forebrains compared to nontransgenic littermates (Fig. 4, A and B) . In addition, we observed a delayed electrophoretic migration of pSer 416 -tau molecules, resulting in the detection of two additional bands of~55 and 60 kDa, as previously documented (Fig. 4A) (41) , which tau epitope and dephosphorylation assays confirmed to be putative hyperphosphorylated 0N4R tau conformers ( fig. S10) (43) .
We next evaluated whether similar changes in CaMKIIa and tau phosphorylation occurred in a second APP transgenic mouse model of AD, the J20 line ( fig. S11) (20) . Because J20 mice were previously shown to generate Ab*56 at 3 to 6 months of age when spatial cognitive deficits are first detected (13), we analyzed the CaMKIIa-tau axis in these mice at 3 months of age. After confirming the presence of Ab*56 in the forebrain tissue of APP transgenic animals, we observed that the phosphorylation of Thr -tau was selectively increased in a similar fashion as that of Tg2576 mice. These findings therefore support the notion that the specific alteration of the CaMKIIa-tau axis by Ab*56 may be a general feature of APP transgenic mouse models of AD.
Consistent with this apparent specificity in the observed pattern of tau hyperphosphorylation, we observed that neither Cdk5 (cyclindependent kinase 5) nor GSK3b (glycogen synthase kinase 3b), two major tau kinases, was abnormally activated in 7-month-old Tg2576 mice or in primary cortical neurons exposed to Ab*56 ( fig. S12) ) were hyperphosphorylated in 7-month-old Tg2576 mice (Fig. 4, A and B) , arguing against their potential involvement in mediating the initial signaling response induced by Ab*56.
Because tau missorting to the PSD alters synaptic function (23, 44, 45), we measured total tau levels in membrane-associated extracts obtained from forebrains of Tg2576 mice at 4, 7, and 12 months of age containing PSD-95, as described elsewhere (2) . First, we observed that both total tau and pSer 416 -tau accumulated with age in membrane-associated lysates from Tg2576 mice. Second, we found that PSD-95 protein levels were decreasing with aging in Tg2576, paralleling the elevation of tau in this compartment (Fig. 4, C and D) . To assess whether tau abnormally cosegregated with PSD-95, we measured the membrane-associated/ intracellular extract ratio of total tau species at 4 and 7 months, which revealed a nearly fivefold rise of tau in the membrane-bound protein fraction of 7-month-old Tg2576 animals (Fig. 4, E and F) . To support these biochemical changes, we performed immunofluorescent labeling followed by confocal imaging analyses (Fig. 4G) . In CA1 pyramidal neurons of 7-month-old Tg2576 mice, there was a marked increase of pSer 202 -tau in the soma and dendrites of the stratum radiatum (Fig. 4G) . By contrast, pSer 416 -tau was nearly exclusively detected in dendrites (Fig. 4G) , matching the distribution of pCaMKIIa (Fig. 3C) To demonstrate that Ab*56 is triggering these pathological changes in tau, we exposed primary cortical neurons to increasing concentrations of Ab*56 previously shown to activate CaMKIIa and examined the phosphorylation and missorting status of tau (Fig. 5) . Mirroring the data observed in 7-month-old Tg2576 mice, tau phosphorylation was unaltered at Tyr , and Ser 409 in the presence of Ab*56 (Fig. 5, A and B) . In contrast, neuronal levels of soluble pSer 202 -tau and pSer 416 -tau rose sharply in a dose-dependent manner in the presence of increasing amounts of Ab*56 (Fig. 5, A and B) . It is worth noting that although purified Ab dimers and trimers can trigger a Fyn-mediated phosphorylation of tau at Tyr 18 (2) , neither species induced hyperphosphorylation of tau at Ser 202 and Ser 416 ( fig. S13 ). Furthermore, we recently reported that Ab trimers could trigger the formation of Alz50-tau conformers in cultured mouse primary cortical neurons in a selective fashion (46) . We therefore measured Alz50-tau abundance in the absence or presence of increasing concentrations of Ab*56 (0 to 25 pM), and we failed to observe any changes in Alz50-positive tau conformers. In parallel, an Ab*56-mediated~2-to 2.5-fold accumulation of tau was observed in membrane-associated lysates containing PSD-95 (Fig. 5, C and D) . Last, we assessed whether these tau changes induced by Ab*56 could also apply to human tau by using Htau primary neurons overexpressing human tau isoforms in the absence of mouse tau. Htau neurons were exposed to Ab*56 for 60 min, and biochemical analysis of tau species present in the intracellular protein-enriched extracts revealed a~3.5-fold elevation of pSer 416 -tau (Fig. 5, E and F Ab*56-induced tau hyperphosphorylation at Ser 416 is dependent on CaMKIIa activity To demonstrate that NMDAR activity is required to mediate the effects of Ab*56, primary neurons were pretreated with the NMDAR-PSD uncoupling peptide tatNR2B9c (47, 48) in the presence or absence of Ab*56. We found that disrupting the interaction between NMDAR and PSD-95 prevented the downstream phosphorylation of CaMKIIa (Fig. 6, A and B, n = 4 to 6 dishes per group, and fig. S14 ) and inhibited the hyperphosphorylation of tau at Ser 202 and Ser 416 induced by Ab*56 (Fig. 6, C and E) , reminiscent of the protection conferred by the peptide from Ab-induced toxicity (49) .
To further demonstrate that the downstream signaling cascade induced by Ab*56 is dependent on CaMKIIa, we applied Ab*56 to primary cultured neurons pretreated with tatCN21, a selective inhibitor of CaMKII (50), for 15 min (Fig. 6) . On the basis of toxicity and target engagement assays, we chose to use this potent inhibitor at 1 mM, a concentration 2-to 10-fold lower than previous reports (51, 52) . As previously described in independent experiments (Fig. 3 ) , a 60-min exposure to Ab*56 triggered a~2.5-fold increase in CaMKIIa phosphorylation at Thr 286 compared to vehicle-treated cells (Fig. 6, F and G). Pretreatment with 1 mM tatCN21 prevented the elevation in pThr 286 -CaMKIIa induced by Ab*56 and, notably, restored CaMKIIa activity to that measured at baseline. As predicted, tatCN21 lowered the baseline levels of active CaMKIIa in the primary neurons.
Once the efficacy and the extent of the inhibition of CaMKIIa were established in the presence of Ab*56, we evaluated a potential rescue of the tau phenotype (Fig. 6, H to J) . In the presence of Ab*56 alone, pS416-tau amounts increased by~2-fold (2.03 ± 9.79) compared to the vehicle control, as shown in Fig. 5 . In addition, a putative tau conformer was readily observed (Fig. 6H) , reminiscent of those observed in vivo (Fig. 4) . Inhibiting CaMKIIa with tatCN21 blocked the aberrant hyperphosphorylation of tau at Ser 416 and prevented the observed electrophoretic shift of tau proteins (Fig. 6, H and I ). Similar observations were obtained for tau phosphorylation at Ser 202 (Fig. 6J) . We also addressed whether inhibiting CaMKIIa could block the apparent missorting of tau triggered by Ab*56. Pretreating cortical neurons with tatCN21 completely abolished the Ab*56-induced translocation of tau to dendrites and into dendritic spines (Fig. 7, A to C) . Moreover, the biochemical segregation of tau into membrane-enriched compartments (2) further supports these findings (Fig.  7 , D and E), indicating that tau hyperphosphorylation at Ser 416 might be necessary to redistribute tau.
DISCUSSION
Here, we found that Ab*56, but not Ab monomers, dimers, or trimers, coimmunoprecipitates with the NMDAR subunits GluN1, GluN2A, and GluN2B in Tg2576 mouse brain tissue in an age-dependent manner. Furthermore, we demonstrated that Ab*56 directly bound to GluN1 and accentuated synaptic NMDARmediated Ca 2+ influx, providing a potential mechanism by which the Ab*56-NMDAR complex is functionally relevant. The detection of this Ab*56-NMDAR complex was associated with abnormally increased activation of CaMKIIa kinase in young Tg2576 mice and in cultured neurons exposed to Ab*56. It is interesting to note that the elevation in CaMKIIa activity measured in vitro (ranging from 1.74-to 3.01-fold increase) was consistent with the 3.4-fold increase in pT286-CaMKIIa detected in 7-month-old Tg2576 mice. Consistent with our current knowledge of CaMKII physiology, the activated kinase translocated to postsynaptic sites in both experimental systems (37) . We also showed that CaMKIIa coupled Ab*56 to the selective phosphorylation and missorting of tau, both in vivo and in vitro, and that this process could be blocked by inhibiting CaMKIIa directly or by uncoupling NMDAR from PSD-95.
Four important concepts emerge from this work. First, the memoryimpairing effects of Ab*56 do not appear to require cell death. We previously highlighted the role of Ab*56 in causing memory deficits in rodents where neurodegeneration is absent (8) . Here, we were able to recapitulate in vitro the phenotypic changes in CaMKIIa and tau observed in vivo, suggesting that the concentrations of Ab*56 applied to cells were comparable to those likely to exist in brain tissue. We have not observed evidence of Ab*56 inducing cell death in vitro or in vivo. This conclusion is supported by the absence of (i) an elevation of LDH release in neurons exposed to Ab*56; (ii) modulations in intracellular messengers classically linked to neuronal cell death, such as the activation of p38 or reductions in ERK/CREB activity (32); and (iii) caspase-3 activation. Together, these findings are consistent with the accumulation of Ab*56 in brain tissue of individuals in their 40s (16) , in which subtle age-related memory decline begins in mid-to-late 30s (17). 
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Second, not all Ab oligomers purified from brain tissue alter the same neuronal signaling pathways. We reported that the detection onset of Ab*56 in the AD mouse model Tg2576 mice at 6 to 7 months of age is associated with a selective activation of CaMKIIa and not other kinases, as well as specific alterations in tau phosphorylation. Furthermore, we went on to demonstrate that exposure to picomolar concentrations of Ab*56 was sufficient to mimic these changes in vitro without modulating intracellular messengers, such as the Src kinase Fyn, ERK, p38, Cdk5, GSK3b, FOXO-1, and CREB. By comparison, purified Ab monomers, dimers, and trimers failed to activate CaMKIIa within the confines of our experimental settings. By contrast, we previously reported that both Ab dimers and trimers purified from AD brain tissue activated Fyn in vitro, whereas Ab*56 did not activate this Src kinase (2) . On the other hand, synthetic mixtures of Ab oligomers activate a combination of several of these kinases (28, 53, 54) . Future studies are needed to determine how CaMKIIa is regulated in the presence of Ab*56 and whether the Ab*56-GluN1 complex is stabilized at the neuronal plasma membrane.
These observations also extend to tau phosphorylation. We previously showed that tau was hyperphosphorylated at Tyr 18 in neurons treated with these low-n Ab oligomers, whereas pY18-tau abundance was unchanged in the presence of Ab*56 (2) . More recently, we reported that Ab trimers selectively induced a pathological conformation change of tau detected by the Alz50 antibody in vitro (46) . Here, we found that Ab dimers and trimers were not affecting tau phosphorylation at Ser 416 , whereas Ab*56 triggered a nearly two-to threefold elevation in pS416-tau amounts. Similarly, Ab*56 induced a dose-dependent hyperphosphorylation of tau at Ser 202 , whereas neither Ab dimers nor trimers triggered this change. These results support the view that distinct oligomeric Ab species exert different effects on neuronal signaling and tau biology. Recent work (3) suggested the involvement of CaMK kinase 2 (CaMKK2) in mediating the toxicity induced by synthetic oligomeric Ab of unknown molecular size, culminating in the hyperphosphorylation of tau at Ser 262 . We did not observe a change of tau phosphorylation at Ser 262 either in Tg2576 and J20 mice or in primary neurons exposed to endogenous oligomeric Ab. Our results are inexplicably inconsistent with the aforementioned published data (3). However, our results are consistent with the current knowledge that CaMKK2 preferentially regulates the activity of CaMKI and CaMKIV, but not CaMKII (55) , and with recent studies assessing the posttranslational modification of tau (56) . In the latter report, the authors compared 32 different tau modifications in two independent experiments using wild-type and J20 APP transgenic mice. None differed significantly and consistently between young J20 and wild-type mice (including at S262) apart from tau phosphorylation at Ser 416 in the PSD (56) . There, pS416-tau was detected at higher frequency (more than twofold). Instead, we consistently found that Ab*56 was inducing the selective hyperphosphorylation of tau at Ser 202 and Ser
416
. The observed hyperphosphorylation of tau at Ser 202 might appear as counterintuitive because it is not a specific substrate of CaMKIIa. In combination with other tau residues, Ser 202 has classically been considered to be a substrate for many kinases including GSK3b, protein kinase A (PKA), Cdk5, and DYRKs (42) . However, we demonstrated in cortical neurons that the hyperphosphorylation of tau at Ser 202 required active CaMKIIa, indicating a hierarchical phosphorylation of tau induced by CaMKIIa, as previously reported for PKA (57) . Functionally, the consequence of tau hyperphosphorylation at Ser 202 by the Ab*56/GluN/ CaMKIIa axis leads to a well-established disruption of microtubule dynamics (58) . Despite the recognition of the apparent specificity of tau posttranslational changes induced by Ab*56 in tau, we also acknowledge that tau is abnormally phosphorylated at many other sites, which may be just as relevant to AD (42) .
Third, the abnormal subcellular distribution of soluble tau species appears to depend on the presence of a distinct hyperphosphorylated epitope. Our dual in vivo labeling approach demonstrated that pS202-tau differed markedly in its cellular distribution from pS416-tau. In particular, the latter did not seem to accumulate in the soma where pS202-tau was abundant. Further studies are needed to determine why some hyperphosphorylated forms of tau are present in the soma and dendrites when other forms are mainly detected in dendrites in vivo.
Fourth, we previously reported that the abundance of Ab*56 in human brain tissue declines with disease progression in a cross-sectional study (16) . Accordingly, previous studies have indicated that CaMKIIa immunoreactivity or pCaMKIIa levels are drastically reduced in AD compared to age-matched controls (59, 60) and that pCaMKIIa is redistributed from the dendrites to the soma in mild cognitive impairment (MCI) and AD hippocampi (61) . Although an exhaustive analysis of CaMKIIa activity in AD is needed to better understand the role of this kinase in pathogenesis, our studies are consistent with the notion that CaMKIIa may be overactive when Ab*56 increases in preclinical AD and suppressed when Ab*56 is lowered in MCI and AD.
Together, our in vivo and in vitro results indicate that different endogenous Ab oligomers alter tau biology in a highly selective manner. It will be interesting in future studies to determine whether homeostatic and pathophysiological processes regulating CaMKIIa in the presence of Ab*56 may contribute to the cellular phase before reaching end-stage AD.
Despite intensive efforts to isolate distinct soluble Ab species and reporting differential effects of Ab oligomers purified from human AD brains on neuronal signaling and tau (2, 46) , it is also fair to indicate intrinsic limitations of our studies: (i) We cannot exclude the possibility that the relative abundance of these species might be altered ex vivo compared to their endogenous state in vivo because of the absence of Ab assembly-specific reagents. (ii) For the same reason, we can also not rule out the possibility that the conformational state of the purified Ab species applied onto neurons will be preserved for the duration of the exposure. (iii) We cannot assume that the concentrations of Ab species used in vitro exactly match those found in vivo; related to this point, it is still unclear whether the current enzyme-linked immunosorbent assay-based approaches can adequately inform on this issue, because qualitative differences in Ab species might be more critical for AD pathophysiology than quantitative differences in total Ab oligomers (62, 63) . (iv) The longitudinal profile of distinct Ab oligomers in aging and in AD is unknown; consequently, the pathophysiological relevance of each separate Ab assembly, including Ab*56, in AD requires further confirmation despite independent reports of a potential link between a putative Ab dodecamer and AD vulnerability in the temporal cortex (18) . (v) We cannot exclude the possibility that other forms of Ab oligomers, not captured by our approach, could affect the Ab*56-activated NMDAR-CaMKIIa-tau pathway (64) . Further work is needed to fill these technical and knowledge gaps, but these studies also provide unprecedented insights into differential molecular mechanisms between Ab oligomers purified from brain tissue.
To conclude, not only are these findings reminiscent of a role of CaMKIIa dysfunction in brain disorders, such as Angelman syndrome -tau, and PSD-95, illustrating the cellular distribution of the pS416-tau/ PSD-95 colocalization channel (yellow) with respect to MAP2 (blue) in neurons treated with vehicle, 2.5 pM Ab*56, or tatCN21 pretreatment (15 min), followed by 2.5 pM Ab*56 for 60 min. Scale bars, 3 mm. (C) Quantitation of the colocalization of pS416-tau with PSD-95 in mouse primary neurons exposed to vehicle, 2.5 pM Ab*56, or tatCN21 pretreatment, followed by 2.5 pM Ab*56. Histograms show means ± SD; one-way ANOVA (F 2,20 = 67.7832, P < 0.0001) followed by Student's t test, ★ P < 0.05 versus vehicle, ☆ P < 0.05 versus Ab*56-treated neurons; n = 8 ROIs per group. (D and E) Western blots (D) and quantitation (E) for soluble tau in membrane-associated lysates from neurons exposed to vehicle, Ab*56, CN21, or Ab*56 + CN21 using the pan tau-specific antibody tau5. Actin was used as internal standard. Histograms show means ± SD; one-way ANOVA (F 3,12 = 197.3191, P < 0.0001) followed by Student's t test; ★ P < 0.05 versus vehicle, ☆ P < 0.05 versus Ab*56-treated neurons; n = 4 dishes per group.
(65), attention deficit hyperactivity disorder (66) , and cerebral ischemia (37) , but also they resonate with the emerging concept that CaMKIIa is altering neuronal physiology and cognition more generally when aberrantly overactivated in the brain. In combination with earlier studies (2, 46) , these results establish that distinct endogenous Ab oligomers activate specific neuronal signaling pathways and that mapping the specific tau changes induced by each of these Ab toxins might provide a general template for monitoring AD progression. In this context, the recent failures of immunotherapies targeting Ab in AD might be due to the fact that these antibodies do not bind the correct type of Ab oligomers or bind specific Ab oligomers with sufficiently high affinities (67) .
Beyond the scope of AD research, we would like to argue that our proof-of-principle approach, that is, identifying the functional and mechanistic properties attributable to a distinct entity of amyloid oligomers, is also relevant for other neurodegenerative disorders including Parkinson's and Huntington's diseases, amyotrophic lateral sclerosis, frontotemporal dementias, and chronic traumatic encephalopathy, where oligomeric forms of amyloid proteins have been proposed to cause both synaptic and cellular toxicity. We should therefore strive to not consider all amyloid oligomers equally toxic but, instead, rigorously assess the role of each molecular assembly separately.
MATERIALS AND METHODS
Transgenic animals
Mice from the APP line Tg2576, which expresses the human APP with the Swedish mutation (APP KM670/671NL ), directed by the hamster prion promoter (68), were purchased from Taconic Farms Inc. and bred to obtain wild-type and hemizygous animals. Mice from the J20, MAPTnull, and Htau lines (20, 69) were purchased from the Jackson Laboratory. J20 animals bred following the guidelines provided by the Mucke Laboratory. Both male and female mice were used in all experiments. All mice were group-housed by gender (aggressive animals were singly housed), given food and water ad libitum, and maintained on a 12-hour light/dark cycle (7:00 a.m./7:00 p.m.). None of the animals analyzed were excluded. All animal procedures and studies were reviewed and approved by the University of Minnesota Institutional Animal Care and Use Committee and Institutional Review Board.
Primary cell cultures
Mouse cortical cultures of neurons were prepared from 14-to 15-dayold embryos, as described previously (2, 70, 71), using 5 × 10 5 cells per dish. After 3 DIV, neurons were treated with 10 mM arabinosylcytosine to inhibit proliferation of nonneuronal cells. All experiments were performed on near-pure neuronal cultures [>98% of MAP2-immunoreactive cells] after 12 to 14 DIV. Three to nine 35-mm dishes per culture per condition were used across three independent experiments.
The concentration and duration of the pretreatments with tatCN21 or with tatNR2B9c were determined by dose response (1, 5, and 10 mM) and time course (15, 30 , and 60 min) experiments using CaMKII and neuronal cell death estimated by LDH assay. Accordingly, pretreatments were set to 15 min at 1 mM for both peptides because longer durations and higher concentrations prove toxic to cells. After treatment(s), cells were harvested in an ice-cold lysis solution containing 50 mM tris-HCl (pH 7.4), 150 mM NaCl, 0.1% Triton X-100 (Sigma) with 1 mM phenylmethylsulfonyl fluoride (PMSF), 2 mM 1,10-phenanthroline monohydrate (1,10-PTH), 1% (v/v) mammalian protease inhibitor cocktail (Sigma), and 0.1% (v/v) phosphatase inhibitor cocktails A [Santa Cruz Biotechnology Inc. (SCBT)] and 2 (Sigma-Aldrich). Cell lysates were centrifuged for 10 min at 13,000g, supernatants were isolated, and corresponding pellets were resuspended with the protease/phosphatase inhibitor-containing lysis buffer to extract membrane-bound proteins. Plasma membranes were solubilized in radioimmunoprecipitation assay (RIPA) lysis buffer [50 mM tris-HCl (pH 7.4), 150 mM NaCl, 0.5% Triton X-100, 1 mM EGTA, 3% SDS, 1% deoxycholate, 1 mM PMSF, 2 mM 1,10-PTH, 1% (v/v) mammalian protease inhibitor cocktail (Sigma), and 0.1% (v/v) phosphatase inhibitor cocktails A (SCBT) and 2 (Sigma-Aldrich)]. Membrane lysates were then subjected to centrifugation for 10 min at 16,000g, and the soluble fraction was removed and stored for analysis.
Neuron transfection
Primary cortical neurons cultures (13 DIV) were transfected with GCaMP6f (gift from L. Looger; Addgene #40755), actin-mCherry (#632589, Clontech Laboratories Inc.), and PSD-95 tagged with yellow fluorescent protein (PSD95-TS:YFP was a gift from R. Tsien; Addgene plasmid #42225) plasmids using the phosphate calcium technique. Cells were exposed to DNA (25 mg/ml) for 30 min. Cells were washed and returned to preconditioning medium supplemented with 5% fetal bovine serum, 5% horse serum, and 1% glutamine. Experiments were performed on 14-DIV cultures. Protrusions with a head localized at less than 5 mm from the dendritic shaft were considered as spines. Our cortical cell cultures display an average of six spines per 10-mm dendrites.
Calcium imaging Experiments were performed as described earlier (26) 
Protein extractions
To analyze Ab species, we harvested one dissected hemi-forebrain per animal and used two extraction protocols described elsewhere (8, 9, 21) . Extracellular-enriched protein extracts refer to protein lysates obtained after the first step of a serial extraction with a lysis buffer composed of 50 mM tris-HCl (pH 7.6), 150 mM NaCl, 0.01% NP-40, 2 mM EDTA, and 0.1% SDS. Samples were then centrifuged at 800g for 10 min at 4°C to separate extracellular lysates from the remaining protein pools [see (21) for details]. In addition, membrane-enriched protein extracts refer to protein lysates obtained after the third step of a serial extraction with a lysis RIPA buffer composed of 50 mM tris-HCl (pH 7.4), 150 mM NaCl, 0.5% Triton X-100, 1 mM EDTA, 3% SDS, and 1% deoxycholate. Samples were then centrifuged at 16,100g for 90 min. Supernatants were collected, and pellets were further extracted with formic acid to analyze fibrillar/deposited proteins. It is possible that the use of the RIPA lysis buffer might strip loosely bound Ab from plaques.
Protein amounts were determined by the Bradford protein assay (BCA Protein Assay, Pierce). All supernatants were ultracentrifuged for 60 min at 100,000g. Finally, before analysis, endogenous Igs were removed from the protein fractions by sequentially incubating extracts for 1 hour at room temperature with 50 ml of Protein A Sepharose Fast Flow followed by 50 ml of Protein G Sepharose Fast Flow (GE Healthcare Life Sciences).
Tau dephosphorylation
Tau (50 mg of intracellular lysate per reaction) was dephosphorylated by treatment with calf-intestinal alkaline phosphatase (New England BioLabs Inc.) at 20 U/ml for 3 hours at 37°C. The reaction was stopped by adding SDS-polyacrylamide gel electrophoresis (SDS-PAGE) loading buffer and heat denaturation at 95°C.
Affinity purification of human Ab oligomers Total brain proteins (1 to 2 mg) from Tg2576 or J20 APP transgenic mice were incubated for 3 hours at 4°C with protein G-coupled magnetic beads (MagG beads, GE Life Sciences) previously cross-linked with 200 mg of purified 6E10 antibody (Covance), with 200 mg of Mab13.1.1 and Mab2.1.3 (100 mg of each), or with 200 mg of GluN1 antibody (Millipore). Immunocaptured proteins were eluted from the immune complexes using 1% n-octyl b-D-thioglucopyranoside (SigmaAldrich) in 100 mM glycine (pH 2.8) for 1 min (three to five rounds).
Relative amounts of purified oligomeric Ab were calculated on the basis of synthetic Ab 1-42 standards (0.001, 0.025, 0.05, 0.1, 0.25, 0.5, 1, and 2.5 ng) ran alongside the samples used for experiments. Because there are no reagents selective to each Ab oligomer to date, we opted to determine the relative abundance of purified Ab oligomers compared to eight Ab standards. The mass of a given Ab oligomer was estimated on the basis of these standards, and molar concentration was calculated on the basis of the empirical molecular weight of each given Ab oligomer (9, 14, and 56 kDa for putative Ab dimers, trimers, and Ab*56, respectively).
Considering that the relative abundance of a given Ab oligomer varies with aging, amyloid deposition, and protein segregation (8, 72, 73) , protein lysates of 15-to 18-month-old APP Tg mice were screened by Western blotting to measure the abundance of apparent Ab dimers, trimers, and Ab*56 before they were subjected to the purification steps consisting of sequential immunoaffinity captures and SEC. Similar segregations were obtained regardless of the line used, although the relative yields for a given oligomeric Ab differed between lines.
Consistent with our previous findings (2, 8, 16, 72, 73) , Ab dimers are far more abundant in membrane-enriched protein lysates compared to extracellular-enriched lysates, whereas this pattern is reversed for putative Ab trimers. Similar biochemical segregation was also observed using postmortem human brain tissue (16) . The example provided in fig. S3 using extracellular lysates reflects this segregation following our four-step extraction protocol.
Size exclusion chromatography
Immunoaffinity-purified protein extracts were loaded on Tricorn Superdex 75 or 200 Increase columns (GE Healthcare Life Sciences) and run at a flow rate of~0.3 ml/min. Fractions of 250 ml of eluate in 50 mM tris-HCl, 150 mM NaCl, and 0.01% Triton X-100 (pH 7.4) were collected using BioLogic DuoFlow QuadTec 40 System (Bio-Rad) coupled to a microplate-format fraction collector. A 280 (absorbance at 280 nm) was determined live during the experiments and confirmed after each run on a DTX800 Multimode microplate reader (Beckman Coulter).
Western blotting and quantification SDS-PAGE was done on precast 10 to 20% SDS-polyacrylamide tristricine gels and 10.5 to 14% and 4 to 10.5% tris-HCl gels (Bio-Rad). Protein levels were normalized to 2 to 100 mg of protein per sample (depending on targeted protein) and resuspended with 4× loading buffer. Thereafter, proteins were transferred onto 0.2-mm nitrocellulose membrane (Bio-Rad) in 5 to 10% methanol-containing transfer buffer for 2 to 3 hours at 4°C. To then detect Ab molecules, nitrocellulose membranes were boiled in 50 ml of phosphate-buffered saline (PBS) by microwaving for 25 and 15 s with a 3-min rest interval in between. Membranes were blocked in tris-buffered saline (TBS)-0.1%Tween 20 (TTBS) containing 5% bovine serum albumin (BSA) (Sigma) for 1 to 2 hours at room temperature and probed with appropriate antisera/ antibodies diluted in 5% BSA-TTBS overnight at 4°C. Primary antibodies were probed with either anti-IgGs conjugated with biotin or infrared dyes (LI-COR Biosciences). When biotin-conjugated secondary antibodies were used, infrared-conjugated NeutrAvidin (Thermo Scientific) was added to amplify the signal. Blots were revealed on an Odyssey platform (LI-COR Biosciences). For the detection of A11-reactive Ab species, all blotting steps were performed in total absence of detergent in the buffers used. When required, membranes were stripped using Restore PLUS Stripping buffer (Pierce) for 30 to 180 min at room temperature depending on antibody affinity. Densitometry was performed using either OptiQuant software (Packard BioScience) or Odyssey software (LI-COR). Each protein of interest was probed in three individual experiments under the same conditions and quantified by software analysis, after determination of experimental conditions ascertaining linearity in the detection of the signal. The method used allows for a dynamic range of~100-fold above background. Respective averages were then determined across the triplicate Western blots. Normalization was performed against the actin or the total form of the studied protein in the case of phosphorylated proteins. Because of the large number of samples analyzed, specimens were processed in two separate ways to compare possible effects induced by aging and by the transgene across groups.
Dot blotting
Two micrograms of membrane-bound protein extracts was mixed with sterile-filtered, deionized water in a total volume of 2.5 ml. Each sample was adsorbed onto a nitrocellulose membrane until dry for 30 min. After a brief activation in 10% methanol-containing TBS, membranes were boiled in PBS to enhance antigen detection (8) . All steps were performed without detergent to enhance A11 and OC binding of oligomeric species (8) .
Immunoprecipitation Aliquots (100 to 250 mg) of protein extracts were diluted to 1 ml with dilution buffer [50 mM tris-HCl (pH 7.4) and 150 mM NaCl] and incubated with appropriate antibodies (5 mg) overnight at 4°C, and 50 ml of Protein G Sepharose Fast Flow (GE Life Sciences) or protein Gcoupled magnetic beads (MagG beads, GE Life Sciences) at 1:1 (v/v) slurry solution with dilution buffer [50 mM tris-HCl (pH 7.4) and 150 mM NaCl (pH 7.4)] was added for 2 to 16 hours. The beads were washed twice in 1 ml of dilution buffer, and proteins were eluted in 25 ml of loading SDS-PAGE buffer by boiling.
Quantitative real-time RT-PCR Total RNAs were extracted with a NucleoSpin RNA II kit (Macherey Nagel) according to the manufacturer's protocol. For each sample, 1 mg of total RNAs was reverse-transcribed using Reverse Transcription System (Promega) and Eppendorf Mastercycler Personal (Bioblock), and RT was first performed at 70°C for 5 min, followed by a second step consisting of RT at 37°C over 1 hour. PCR amplification was performed on 5 ml of RT products in a total volume of 25 ml. Forward and reverse primers were designed with Beacon Designer software (Bio-Rad) and used after validation. Assays were made in triplicate using the iCycler iQ real-time PCR detection system (Bio-Rad). The amplification profile was as follows: 95°C for 30 s (twice), 95°C for 15 min (once), and 40 cycles in 15 s at 95°C, 1 min at 60°C, and 30 s at 95°C. PCR was run using the ABsolute QPCR SYBR Green Fluorescein Mix (ABgene) and its associated protocol. The amount of target was given by the following formula: 2 − [(C t gene of interest − C t housekeeping gene)T -(C t gene of interest − C t housekeeping gene)C], where C t is the threshold cycle value, T is the treated condition, and C is the control condition. Results are expressed relative to the housekeeping genes cyclophilin and actin.
Confocal imaging
Triple-or quadruple-label immunofluorescence was performed as previously described (2, 19) using Alexa Fluor 488-, Alexa Fluor 555-, and Alexa Fluor 635-conjugated secondary antibodies (Molecular Probes, Invitrogen). Mouse brain sections were treated for autofluorescence with 1% Sudan Black solution and coverslipped with ProLong mounting medium (Molecular Probes). Digital images were obtained using an Olympus IX81 FluoView 1000 microscope with laser intensities ranging from 7 to 11%. Raw image z stacks (0.1-to 0.5-mm intervals) were analyzed using Bitplane's Imaris 7.x software suite. Frame size was maintained at 1024 × 800, and optical zoom of 1.00 was used to allow for maximum distribution of pixel size to tissue dimensions without oversampling. Six ROIs per brain section (six sections per brain) per animal (four to six animals per group) were used in a randomized fashion. For in vitro analyses, eight ROIs per dish per group were used. Z stacks were reconstructed using the Surpass or Easy3D modules of the Imaris software package (version 7.x, Bitplane Inc.). Experimenters performing image acquisition and analyses were blind to the genotype or treatment conditions.
Statistical analyses
When variables were non-normally distributed, nonparametric statistics were used (Spearman rho correlation coefficients and Kruskal-Wallis nonparametric analysis of variance followed by Bonferroni-corrected two-group post hoc Mann-Whitney U tests). When variables were normally distributed, parametric statistics were used (one-or two-way ANOVA followed by Bonferroni-corrected two-group post hoc Student's t tests). Sample size was determined by power analysis to be able to detect statistically significant changes within a 20% variation of measured responses. Analyses were performed using JMP 11 (SAS Institute).
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www.sciencesignaling.org/cgi/content/full/10/478/eaal2021/DC1 Fig. S1 . Reverse coimmunoprecipitation of Ab*56 with NMDAR subunits in Tg2576 and in human brain tissue. 
